Key Highlights
- The FDA has granted Priority Review to Roche’s Gazyva/Gazyvaro (obinutuzumab) for primary membranous nephropathy (pMN), with a regulatory decision expected by November 2026, potentially making it the first-ever FDA-approved therapy for the disease.
- The designation is backed by Phase III MAJESTY trial data showing a 36.9% complete remission rate versus just 5.7% for tacrolimus, a 31.1-percentage-point difference, along with superiority on key secondary endpoints at week 76 and week 104.
- This marks Roche’s second Priority Review for obinutuzumab in recent months, following a similar designation for idiopathic nephrotic syndrome in May 2026, underscoring the growing breadth of the molecule’s clinical program beyond its oncology origins.
A Landmark Regulatory Milestone for a Disease With No Approved Treatments
Roche’s announcement that the FDA has granted Priority Review to Gazyva/Gazyvaro for primary membranous nephropathy marks a pivotal moment for a patient population that has long gone without a dedicated, approved therapy. pMN is a chronic autoimmune disease in which the immune system attacks the kidney’s glomeruli, causing protein leakage and progressive kidney damage that can result in irreversible failure. With up to 30% of untreated patients progressing to kidney failure within a decade, the potential arrival of the first FDA-approved treatment for this condition represents a meaningful step forward for nephrology care.
Inside the Data: What the MAJESTY Trial Revealed
The Priority Review designation rests on compelling Phase III evidence. The MAJESTY study enrolled 142 adults with pMN, randomized 1:1 to receive Gazyva/Gazyvaro or the immunosuppressive therapy tacrolimus, the current off-label standard of care. Gazyva/Gazyvaro achieved a complete remission rate of 36.9% compared to just 5.7% for tacrolimus, a 31.1-point adjusted difference that Roche and independent observers alike have characterized as a clinically meaningful gap. The therapy also demonstrated superiority in overall remission at week 104 and complete remission at week 76, with a safety profile consistent with Gazyva/Gazyvaro’s established experience and no new safety signals identified.
The Science Behind the Success: Targeting Tissue-Resident B Cells
Unlike broad immunosuppression, Gazyva/Gazyvaro works by targeting tissue-resident B cells, addressing what Roche describes as an underlying driver of pMN rather than simply suppressing the immune system’s overall activity. “By targeting tissue-resident B cells, Gazyva/Gazyvaro addresses an underlying cause of pMN and has the potential to help more patients achieve complete remission, a necessary step to maintaining kidney function,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. The FDA had already recognized this potential in April 2026, granting Breakthrough Therapy Designation ahead of this latest Priority Review.
Part of a Bigger Pattern: Obinutuzumab’s Expanding Reach Across Kidney and Immune Disease
This Priority Review is the latest in a fast-accumulating series of regulatory milestones for obinutuzumab. It follows an equivalent Priority Review for idiopathic nephrotic syndrome granted in May 2026, and Roche has also filed for approval in systemic lupus erythematosus following positive Phase III ALLEGORY data, with a decision expected by December 2026. Gazyva/Gazyvaro is already approved for lupus nephritis in the US and EU. Together, these developments illustrate how Roche is methodically building obinutuzumab into a foundational therapy across multiple immune-mediated kidney and autoimmune diseases, reinforcing the molecule’s expanding role well beyond its original oncology indications.
By